# ObesityCVHypoMap - Top Hypothesis Cards

본 도구는 연구용/참고용입니다. 임상의사결정에 직접 사용하지 마십시오. 생성된 가설은 IRB 승인과 전문가 검토를 거친 후에만 활용하십시오. 항비만 약물의 CV outcome 권고는 학회 가이드라인을 우선시하십시오.

### #1. tirzepatide (Zepbound/Mounjaro) -> HF with preserved EF (HF) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.78 (gap=1.00, faers=0.00, trial_korea=1.00, preprint=0.70, mediation=1.00, korea_rwe=0.79)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=yes, active trial=yes (Korea sites=5)
- **Suggested N**: 25000 (power ~18% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2002
- **Rationale**: PubMed 미탐색 cell; medRxiv pre-publication signal; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #2. tirzepatide (Zepbound/Mounjaro) -> Myocardial infarction (MACE) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.24 (gap=1.00, faers=0.00, trial_korea=0.90, preprint=0.00, mediation=1.00, korea_rwe=0.88)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=4)
- **Suggested N**: 18779 (power ~30% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2003
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #3. tirzepatide (Zepbound/Mounjaro) -> Myocardial infarction (MACE) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.21 (gap=1.00, faers=0.00, trial_korea=0.90, preprint=0.00, mediation=1.00, korea_rwe=0.85)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=4)
- **Suggested N**: 23901 (power ~25% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2003
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #4. tirzepatide (Zepbound/Mounjaro) -> HF with preserved EF (HF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.16 (gap=1.00, faers=0.00, trial_korea=1.00, preprint=0.00, mediation=1.00, korea_rwe=0.74)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=5)
- **Suggested N**: 25000 (power ~12% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2002
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #5. tirzepatide (Zepbound/Mounjaro) -> HF with preserved EF (HF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.14 (gap=1.00, faers=0.00, trial_korea=1.00, preprint=0.00, mediation=1.00, korea_rwe=0.72)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=5)
- **Suggested N**: 25000 (power ~10% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2002
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #6. tirzepatide (Zepbound/Mounjaro) -> Myocardial infarction (MACE) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.14 (gap=1.00, faers=0.00, trial_korea=0.90, preprint=0.00, mediation=1.00, korea_rwe=0.80)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=4)
- **Suggested N**: 25000 (power ~16% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2003
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #7. tirzepatide (Zepbound/Mounjaro) -> Paroxysmal AF (AF) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.14 (gap=1.00, faers=0.63, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.91)
- **Evidence**: PubMed n=0, FAERS PRR=1.90, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 16693 (power ~34% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.90; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #8. tirzepatide (Zepbound/Mounjaro) -> Myocardial infarction (MACE) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.12 (gap=1.00, faers=0.00, trial_korea=0.90, preprint=0.00, mediation=1.00, korea_rwe=0.79)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=4)
- **Suggested N**: 25000 (power ~13% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2003
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #9. tirzepatide (Zepbound/Mounjaro) -> Right ventricular dysfunction (HF) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.10 (gap=1.00, faers=0.80, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.72)
- **Evidence**: PubMed n=0, FAERS PRR=2.40, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~10% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.40; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #10. tirzepatide (Zepbound/Mounjaro) -> Paroxysmal AF (AF) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.10 (gap=1.00, faers=0.63, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.88)
- **Evidence**: PubMed n=0, FAERS PRR=1.90, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 21245 (power ~27% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.90; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #11. tirzepatide (Zepbound/Mounjaro) -> HF with preserved EF (HF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.09 (gap=1.00, faers=0.00, trial_korea=1.00, preprint=0.00, mediation=1.00, korea_rwe=0.69)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=5)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2002
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #12. tirzepatide (Zepbound/Mounjaro) -> Myocardial infarction (MACE) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.07 (gap=1.00, faers=0.00, trial_korea=0.90, preprint=0.00, mediation=1.00, korea_rwe=0.75)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=4)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2003
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #13. tirzepatide (Zepbound/Mounjaro) -> Right ventricular dysfunction (HF) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.06 (gap=1.00, faers=0.80, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.69)
- **Evidence**: PubMed n=0, FAERS PRR=2.40, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~9% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.40; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #14. tirzepatide (Zepbound/Mounjaro) -> Paroxysmal AF (AF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.03 (gap=1.00, faers=0.63, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.82)
- **Evidence**: PubMed n=0, FAERS PRR=1.90, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~17% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.90; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #15. setmelanotide (Imcivree) -> Paroxysmal AF (AF) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.03 (gap=1.00, faers=1.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.48)
- **Evidence**: PubMed n=0, FAERS PRR=3.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 16693 (power ~34% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=3.00; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #16. semaglutide 2.4mg (Wegovy) -> Paroxysmal AF (AF) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.02 (gap=1.00, faers=0.53, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.91)
- **Evidence**: PubMed n=0, FAERS PRR=1.60, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 16693 (power ~34% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.60; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #17. tirzepatide (Zepbound/Mounjaro) -> Paroxysmal AF (AF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.02 (gap=1.00, faers=0.63, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.81)
- **Evidence**: PubMed n=0, FAERS PRR=1.90, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~14% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.90; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #18. tirzepatide (Zepbound/Mounjaro) -> Right ventricular dysfunction (HF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 4.00 (gap=1.00, faers=0.80, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.65)
- **Evidence**: PubMed n=0, FAERS PRR=2.40, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~7% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.40; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #19. setmelanotide (Imcivree) -> Paroxysmal AF (AF) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.99 (gap=1.00, faers=1.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.46)
- **Evidence**: PubMed n=0, FAERS PRR=3.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 21245 (power ~27% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=3.00; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #20. tirzepatide (Zepbound/Mounjaro) -> Right ventricular dysfunction (HF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.98 (gap=1.00, faers=0.80, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.63)
- **Evidence**: PubMed n=0, FAERS PRR=2.40, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~6% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.40; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #21. semaglutide 2.4mg (Wegovy) -> Paroxysmal AF (AF) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.98 (gap=1.00, faers=0.53, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.88)
- **Evidence**: PubMed n=0, FAERS PRR=1.60, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 21245 (power ~27% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.60; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #22. tirzepatide (Zepbound/Mounjaro) -> Paroxysmal AF (AF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.96 (gap=1.00, faers=0.63, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.77)
- **Evidence**: PubMed n=0, FAERS PRR=1.90, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.90; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #23. semaglutide 2.4mg (Wegovy) -> HF with preserved EF (HF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.96 (gap=1.00, faers=0.00, trial_korea=0.80, preprint=0.00, mediation=1.00, korea_rwe=0.74)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=3)
- **Suggested N**: 25000 (power ~12% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2001
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #24. semaglutide 2.4mg (Wegovy) -> HF with preserved EF (HF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.94 (gap=1.00, faers=0.00, trial_korea=0.80, preprint=0.00, mediation=1.00, korea_rwe=0.72)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=3)
- **Suggested N**: 25000 (power ~10% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2001
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #25. tirzepatide (Zepbound/Mounjaro) -> Right ventricular dysfunction (HF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.93 (gap=1.00, faers=0.80, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.59)
- **Evidence**: PubMed n=0, FAERS PRR=2.40, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~4% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.40; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #26. setmelanotide (Imcivree) -> Paroxysmal AF (AF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.93 (gap=1.00, faers=1.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.41)
- **Evidence**: PubMed n=0, FAERS PRR=3.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~17% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=3.00; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #27. semaglutide 2.4mg (Wegovy) -> Paroxysmal AF (AF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.91 (gap=1.00, faers=0.53, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.82)
- **Evidence**: PubMed n=0, FAERS PRR=1.60, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~17% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.60; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #28. setmelanotide (Imcivree) -> Paroxysmal AF (AF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.91 (gap=1.00, faers=1.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.39)
- **Evidence**: PubMed n=0, FAERS PRR=3.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~14% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=3.00; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #29. semaglutide 2.4mg (Wegovy) -> Paroxysmal AF (AF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.90 (gap=1.00, faers=0.53, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.81)
- **Evidence**: PubMed n=0, FAERS PRR=1.60, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~14% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.60; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #30. semaglutide 2.4mg (Wegovy) -> HF with preserved EF (HF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.89 (gap=1.00, faers=0.00, trial_korea=0.80, preprint=0.00, mediation=1.00, korea_rwe=0.69)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=3)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / NCT_MOCK_2001
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #31. setmelanotide (Imcivree) -> Paroxysmal AF (AF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.86 (gap=1.00, faers=1.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.35)
- **Evidence**: PubMed n=0, FAERS PRR=3.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=3.00; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #32. semaglutide 2.4mg (Wegovy) -> Paroxysmal AF (AF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.84 (gap=1.00, faers=0.53, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.77)
- **Evidence**: PubMed n=0, FAERS PRR=1.60, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=1.60; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #33. orforglipron (oral GLP-1) -> Cardiovascular death (MACE) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.75 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.65)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~24% for HR 0.80)
- **Korea IIS/RWE potential**: moderate
- **Mock IDs**: - / NCT_MOCK_2006
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #34. orforglipron (oral GLP-1) -> Cardiovascular death (MACE) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.71 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.62)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~20% for HR 0.80)
- **Korea IIS/RWE potential**: moderate
- **Mock IDs**: - / NCT_MOCK_2006
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #35. orforglipron (oral GLP-1) -> Ischemic stroke (MACE) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.70 (gap=1.00, faers=0.00, trial_korea=0.00, preprint=0.70, mediation=1.00, korea_rwe=0.72)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=yes, active trial=no (Korea sites=0)
- **Suggested N**: 17382 (power ~32% for HR 0.80)
- **Korea IIS/RWE potential**: moderate
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; medRxiv pre-publication signal; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #36. orforglipron (oral GLP-1) -> Cardiovascular death (MACE) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.64 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.57)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~13% for HR 0.80)
- **Korea IIS/RWE potential**: moderate
- **Mock IDs**: - / NCT_MOCK_2006
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #37. orforglipron (oral GLP-1) -> Cardiovascular death (MACE) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.62 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.56)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~11% for HR 0.80)
- **Korea IIS/RWE potential**: moderate
- **Mock IDs**: - / NCT_MOCK_2006
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #38. retatrutide (LY3437943) -> Persistent AF (AF) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.57 (gap=1.00, faers=0.70, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.41)
- **Evidence**: PubMed n=0, FAERS PRR=2.10, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~24% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.10; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #39. orforglipron (oral GLP-1) -> Cardiovascular death (MACE) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.57 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.52)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: moderate
- **Mock IDs**: - / NCT_MOCK_2006
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #40. retatrutide (LY3437943) -> Persistent AF (AF) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.53 (gap=1.00, faers=0.70, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.38)
- **Evidence**: PubMed n=0, FAERS PRR=2.10, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~20% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.10; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #41. retatrutide (LY3437943) -> Persistent AF (AF) in Obesity + sleep apnea
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.47 (gap=1.00, faers=0.70, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.33)
- **Evidence**: PubMed n=0, FAERS PRR=2.10, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~13% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.10; dominant mediation: Weight loss pathway; phenotype 한국유병률 12.0%

### #42. retatrutide (LY3437943) -> Persistent AF (AF) in Sarcopenic obesity
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.45 (gap=1.00, faers=0.70, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.32)
- **Evidence**: PubMed n=0, FAERS PRR=2.10, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~11% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.10; dominant mediation: Weight loss pathway; phenotype 한국유병률 9.5%

### #43. retatrutide (LY3437943) -> Cardiovascular death (MACE) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.43 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.41)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~24% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / NCT_MOCK_2004
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #44. semaglutide 2.4mg (Wegovy) -> Ischemic stroke (MACE) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.41 (gap=1.00, faers=0.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.93)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 13658 (power ~40% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #45. tirzepatide (Zepbound/Mounjaro) -> Ischemic stroke (MACE) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.41 (gap=1.00, faers=0.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.93)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 13658 (power ~40% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #46. retatrutide (LY3437943) -> Persistent AF (AF) in Post-bariatric obesity (재발)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.40 (gap=1.00, faers=0.70, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.28)
- **Evidence**: PubMed n=0, FAERS PRR=2.10, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~5% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.10; dominant mediation: Weight loss pathway; phenotype 한국유병률 1.5%

### #47. CagriSema (cagrilintide+semaglutide) -> Myocardial infarction (MACE) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.40 (gap=1.00, faers=0.00, trial_korea=0.60, preprint=0.00, mediation=1.00, korea_rwe=0.46)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=1)
- **Suggested N**: 18779 (power ~30% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / NCT_MOCK_2005
- **Rationale**: PubMed 미탐색 cell; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #48. CagriSema (cagrilintide+semaglutide) -> Right ventricular dysfunction (HF) in Obesity + T2DM
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.40 (gap=1.00, faers=0.67, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.30)
- **Evidence**: PubMed n=0, FAERS PRR=2.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 25000 (power ~10% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; FAERS signal PRR=2.00; dominant mediation: Weight loss pathway; phenotype 한국유병률 28.0%

### #49. retatrutide (LY3437943) -> Cardiovascular death (MACE) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.39 (gap=1.00, faers=0.00, trial_korea=0.70, preprint=0.00, mediation=1.00, korea_rwe=0.38)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=yes (Korea sites=2)
- **Suggested N**: 25000 (power ~20% for HR 0.80)
- **Korea IIS/RWE potential**: low
- **Mock IDs**: - / NCT_MOCK_2004
- **Rationale**: PubMed 미탐색 cell; active trial + 한국 사이트; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%

### #50. semaglutide 2.4mg (Wegovy) -> Ischemic stroke (MACE) in Lean diabetic Asian (BMI 23-27)
- **Dominant mediation**: Weight loss pathway (surrogate: % TBWL (W12, W24, W52))
- **Analysis model**: natural direct/indirect effect (Imai-Keele-Tingley)
- **Score**: 3.37 (gap=1.00, faers=0.00, trial_korea=0.00, preprint=0.00, mediation=1.00, korea_rwe=0.90)
- **Evidence**: PubMed n=0, FAERS PRR=0.00, preprint=no, active trial=no (Korea sites=0)
- **Suggested N**: 17382 (power ~32% for HR 0.80)
- **Korea IIS/RWE potential**: high
- **Mock IDs**: - / -
- **Rationale**: PubMed 미탐색 cell; dominant mediation: Weight loss pathway; phenotype 한국유병률 22.0%


_총 495 cell 중 top 50 출력. score = 1.5*gap + 1.2*FAERS + 1.0*trial+한국 + 0.8*preprint + 0.7*mediation + 1.3*korea_rwe._